You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

ZYRTEC Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ZYRTEC?
  • What are the global sales for ZYRTEC?
  • What is Average Wholesale Price for ZYRTEC?
Summary for ZYRTEC
US Patents:0
Applicants:1
NDAs:4
Raw Ingredient (Bulk) Api Vendors: 119
Clinical Trials: 30
Patent Applications: 2,616
Drug Sales Revenues: Drug sales revenues for ZYRTEC
What excipients (inactive ingredients) are in ZYRTEC?ZYRTEC excipients list
DailyMed Link:ZYRTEC at DailyMed
Drug patent expirations by year for ZYRTEC
Drug Sales Revenue Trends for ZYRTEC

See drug sales revenues for ZYRTEC

Recent Clinical Trials for ZYRTEC

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Emory UniversityPhase 4
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare DivisionPhase 1
Indiana UniversityPhase 4

See all ZYRTEC clinical trials

Paragraph IV (Patent) Challenges for ZYRTEC
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ZYRTEC Syrup cetirizine hydrochloride 5 mg/5 mL 020346 1 2007-03-19

US Patents and Regulatory Information for ZYRTEC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
J And J Consumer Inc ZYRTEC cetirizine hydrochloride SOLUTION;ORAL 020346-001 Sep 27, 1996 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
J And J Consumer Inc ZYRTEC-D 12 HOUR cetirizine hydrochloride; pseudoephedrine hydrochloride TABLET, EXTENDED RELEASE;ORAL 021150-002 Nov 9, 2007 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
J And J Consumer Inc ZYRTEC ALLERGY cetirizine hydrochloride TABLET;ORAL 019835-004 Nov 16, 2007 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
J And J Consumer Inc ZYRTEC ALLERGY cetirizine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 022578-001 Sep 3, 2010 OTC Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ZYRTEC

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0058146 SPC/GB01/052 United Kingdom ⤷  Sign Up SPC/GB01/052:, EXPIRES: 20070205
0663828 C300085 Netherlands ⤷  Sign Up PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
0058146 2001C/045 Belgium ⤷  Sign Up PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.